论文部分内容阅读
目的探讨乳腺癌患者外周血中单个核细胞(PBMC)中C-erbB-2的表达水平及其与肿瘤组织中C-erbB-2、激素受体(ER、PR)表达状态及与病期的相关性。方法采用流式细胞术检测77例乳腺癌患者PBMC中C-erbB-2表达水平并与肿瘤组织中C-erbB-2、激素受体(ER、PR)表达状态及与病期进行比较。结果77例乳腺癌患者PBMC中C-erbB-2检测水平为(24.16±20.81)%。瘤组织中C-erbB-2阳性者的PBMC中的C-erbB-2值(30.69±21.70)%,高于瘤组织C-erbB-2阴性值(17.47±17.48)%,2者有显著性差异(P<0.01)。肿瘤组织中激素受体阴性与阳性者、临床分期Ⅲ~Ⅵ患者与Ⅰ~Ⅱ期患者PBMC的C-erbB-2均值无明显差别(P>0.05)。结论乳腺癌患者PBMC中C-erbB-2的表达水平与瘤组织中C-erbB-2的表达状态密切相关,与病期、瘤组织的激素受体表达状态无关。为进一步用FCM研究外周血中C-erbB-2对预后判断的影响及用于指导治疗提供依据。
Objective To investigate the expression of C-erbB-2 in peripheral blood mononuclear cells (PBMCs) of breast cancer patients and its relationship with the expression of C-erbB-2, hormone receptor (ER, PR) Correlation. Methods The expression of C-erbB-2 in PBMC from 77 patients with breast cancer was detected by flow cytometry and compared with the expression of C-erbB-2, ER and PR in tumor tissue. Results The level of C-erbB-2 in PBMC of 77 breast cancer patients was (24.16 ± 20.81)%. The C-erbB-2 value (30.69 ± 21.70)% in PBMCs of C-erbB-2 positive patients was higher than that of the C-erbB-2 negative tumors (17.47 ± 17.48)% Difference (P <0.01). There were no significant differences in the mean C-erbB-2 levels of PBMC between the clinical stage Ⅲ-Ⅵ patients and the stage Ⅰ-Ⅱpatients with hormone receptor negative and positive tumor tissues (P> 0.05). Conclusion The expression of C-erbB-2 in PBMC of breast cancer patients is closely related to the expression of C-erbB-2 in the tumor tissue, but not with the expression of hormone receptor in the stage and tumor tissues. To further use FCM to study the influence of C-erbB-2 in peripheral blood on the prognosis and provide the basis for guiding the treatment.